DoseMe, a global provider of model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, announced the acquisition of Firstline, a worldwide clinical decision support platform. Firstline delivers rapid access to localized, evidence-based infectious disease treatment guidance, susceptibility data, and antimicrobial stewardship (AMS) tools. The integration of both companies forms a unified platform that streamlines therapy selection and personalized dosing, providing clinicians with a more efficient path to optimal treatment.
“Firstline is the perfect complement to DoseMe with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance,” said Paul Edwards, CEO of DoseMe. “Together, we support AMS initiatives and speed up optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing.”
Antibiotic-resistant infections represent a growing global healthcare challenge, imposing an estimated $21 – 34 billion annual cost on the U.S. healthcare system and contributing to over 8 million excess hospital days. Health systems increasingly require integrated solutions that turn antimicrobial stewardship policies into actionable insights at the point of care.
“We’re immensely proud to have built Firstline into an organization delivering clinical guidance globally to hospitals, governments and the World Health Organization,” said Dr. Michael Long, co-founder and Chief Clinical Officer of Firstline. “We’re excited to see Firstline continue to flourish as part of the larger DoseMe organization.”
“The combination of DoseMe and Firstline advances the mission to address the full patient care continuum of personalized medicine. We look forward to the consolidated business’ continued growth, but most importantly to the profound impact this combination will have on the customer’s ability to improve patient care,” said David Neiman, Managing Partner at Fairlong Capital.